27Feb 2022
Preventing all‐cause hospitalizations in type‐2 diabetes with SGLT2 inhibitors and GLP‐1 receptor agonists – narrative review and clinical approach

Preventing all‐cause hospitalizations in type‐2 diabetes with SGLT2 inhibitors and GLP‐1 receptor agonists – narrative review and clinical approach

Patients with type‐2 diabetes (T2D) are at increased risk for hospital admissions, and acute hospitalizations are associated with a worse prognosis. However, outcomes related to all‐cause hospital admissions (ACHA) were often overlooked in the trials that demonstrated the cardiovascular and kidney benefits of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs). This review includes a contemporary literature summary of emerging data regarding the effects of SGLT2i and GLP‐1 RAs on ACHA. SGLT2i role in preventing ACHA was shown in exploratory investigations of several randomized controlled trials (RCTs) and was further supported by real‐world evidence (RWE). However, the association between GLP‐1 RAs use and lower ACHA risk was mainly shown with RWE, with minimal available RCTs data. Finally, it proposes an easily memorized (‘ABCDE’ acronym) clinical approach to evaluating T2D status and treatment in admitted patients, as they transition from hospital to community care. This systematic approach may assist clinicians in recognizing possible pitfalls in T2D management, thereby preventing subsequent hospitalizations and improving patients’ prognoses. While acute admission can sometimes be perceived as a management failure, it should also be viewed as an opportunity to take action to prevent the next hospitalization.

  • #endo-diabetology

Like

Save

Share